A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

Talitha I Verhoef; William K Redekop; Josep Darba; Mary Geitona; Dyfrig A Hughes; Uwe Siebert; Anthonius de Boer; Anke-Hilse Maitland-van der Zee; Rita Barallon; Montserrat Briz; Ann Daly; Elisabeth Haschke-Becher; Farhad Kamali; Julia Kirchheiner; Vangelis G Manolopoulos; Munir Pirmohamed; Frits R Rosendaal; Rianne M F van Schie; Mia Wadelius

doi:10.2217/pgs.10.74

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

Talitha I Verhoef, William K Redekop, Josep Darba, Mary Geitona, Dyfrig A Hughes, Uwe Siebert, Anthonius de Boer, Anke-Hilse Maitland-van der Zee, Rita Barallon, Montserrat Briz, Ann Daly, Elisabeth Haschke-Becher (Co-author), Farhad Kamali, Julia Kirchheiner, Vangelis G Manolopoulos, Munir Pirmohamed, Frits R Rosendaal, Rianne M F van Schie, Mia Wadelius

Research output: Contribution to journal › Review article › peer-review

21 Citations (Web of Science)

Original language	English
Pages (from-to)	989-1002
Journal	PHARMACOGENOMICS
Volume	11
Issue number	7
DOIs	https://doi.org/10.2217/pgs.10.74
Publication status	Published - 2010

Keywords

ORAL ANTICOAGULANT-THERAPY
INTERNATIONAL NORMALIZED RATIO
WARFARIN THERAPY
BLEEDING COMPLICATIONS
ATRIAL-FIBRILLATION
CYTOCHROME P4502C9
ECONOMIC OUTCOMES
DOSE REQUIREMENT
CYP2C9
VKORC1

Access to Document

10.2217/pgs.10.74

Cite this

Verhoef, T. I., Redekop, W. K., Darba, J., Geitona, M., Hughes, D. A., Siebert, U., de Boer, A., Maitland-van der Zee, A.-H., Barallon, R., Briz, M., Daly, A., Haschke-Becher, E., Kamali, F., Kirchheiner, J., Manolopoulos, V. G., Pirmohamed, M., Rosendaal, F. R., van Schie, R. M. F., & Wadelius, M. (2010). A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. PHARMACOGENOMICS, 11(7), 989-1002. https://doi.org/10.2217/pgs.10.74

@article{f90f61305c4b41dca40e527a133b9d7f,

title = "A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.",

keywords = "ORAL ANTICOAGULANT-THERAPY, INTERNATIONAL NORMALIZED RATIO, WARFARIN THERAPY, BLEEDING COMPLICATIONS, ATRIAL-FIBRILLATION, CYTOCHROME P4502C9, ECONOMIC OUTCOMES, DOSE REQUIREMENT, CYP2C9, VKORC1",

author = "Verhoef, {Talitha I} and Redekop, {William K} and Josep Darba and Mary Geitona and Hughes, {Dyfrig A} and Uwe Siebert and {de Boer}, Anthonius and {Maitland-van der Zee}, Anke-Hilse and Rita Barallon and Montserrat Briz and Ann Daly and Elisabeth Haschke-Becher and Farhad Kamali and Julia Kirchheiner and Manolopoulos, {Vangelis G} and Munir Pirmohamed and Rosendaal, {Frits R} and {van Schie}, {Rianne M F} and Mia Wadelius",

year = "2010",

doi = "10.2217/pgs.10.74",

language = "English",

volume = "11",

pages = "989--1002",

journal = "PHARMACOGENOMICS",

issn = "1462-2416",

publisher = "Future Medicine ",

number = "7",

}

Verhoef, TI, Redekop, WK, Darba, J, Geitona, M, Hughes, DA, Siebert, U, de Boer, A, Maitland-van der Zee, A-H, Barallon, R, Briz, M, Daly, A, Haschke-Becher, E, Kamali, F, Kirchheiner, J, Manolopoulos, VG, Pirmohamed, M, Rosendaal, FR, van Schie, RMF & Wadelius, M 2010, 'A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.', PHARMACOGENOMICS, vol. 11, no. 7, pp. 989-1002. https://doi.org/10.2217/pgs.10.74

TY - JOUR

T1 - A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

AU - Verhoef, Talitha I

AU - Redekop, William K

AU - Darba, Josep

AU - Geitona, Mary

AU - Hughes, Dyfrig A

AU - Siebert, Uwe

AU - de Boer, Anthonius

AU - Maitland-van der Zee, Anke-Hilse

AU - Barallon, Rita

AU - Briz, Montserrat

AU - Daly, Ann

AU - Haschke-Becher, Elisabeth

AU - Kamali, Farhad

AU - Kirchheiner, Julia

AU - Manolopoulos, Vangelis G

AU - Pirmohamed, Munir

AU - Rosendaal, Frits R

AU - van Schie, Rianne M F

AU - Wadelius, Mia

PY - 2010

Y1 - 2010

KW - ORAL ANTICOAGULANT-THERAPY

KW - INTERNATIONAL NORMALIZED RATIO

KW - WARFARIN THERAPY

KW - BLEEDING COMPLICATIONS

KW - ATRIAL-FIBRILLATION

KW - CYTOCHROME P4502C9

KW - ECONOMIC OUTCOMES

KW - DOSE REQUIREMENT

KW - CYP2C9

KW - VKORC1

U2 - 10.2217/pgs.10.74

DO - 10.2217/pgs.10.74

M3 - Review article

C2 - 20602617

SN - 1462-2416

VL - 11

SP - 989

EP - 1002

JO - PHARMACOGENOMICS

JF - PHARMACOGENOMICS

IS - 7

ER -